Press release
Cutaneous Lupus Erythematosus Clinical Trial Pipeline Accelerates as 10+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Stay ahead in understanding the Cutaneous Lupus Erythematosus Treatment Landscape @ Cutaneous Lupus Erythematosus Pipeline Outlook [https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Cutaneous Lupus Erythematosus Pipeline Report
* On March 12, 2026- Biogen initiated a study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue.
* On March 11, 2026- AstraZeneca conducted a Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
* On March 11, 2026- Ventus Therapeutics U.S. Inc. announced a clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body.
* DelveInsight's Cutaneous Lupus Erythematosus pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Cutaneous Lupus Erythematosus treatment.
* The leading Cutaneous Lupus Erythematosus Companies such as Hoth Therapeutics, Zylo Therapeutics, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, and Horizon Therapeutics and others.
* Promising Cutaneous Lupus Erythematosus Pipeline Therapies such as Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran, and others.
Gain in-depth knowledge of key Cutaneous Lupus Erythematosus Clinical Trials @ Cutaneous Lupus Erythematosus Clinical Trials Assessment [https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cutaneous Lupus Erythematosus Overview
Lupus erythematosus (LE) is a connective tissue disease and autoimmune disorder that can affect one or several organs. Circulating autoantibodies and immune complexes are due to loss of normal immune tolerance and are pathogenic. The clinical features of LE are highly variable. LE nearly always affects the skin to some degree. Cutaneous LE comprises several chronic and relapsing LE-specific and LE-nonspecific inflammatory conditions
Cutaneous Lupus Erythematosus Emerging Drugs Profile
* BIIB059: Biogen
Litifilimab (known as BIIB059), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Currently it is being evaluated in Phase II clinical trial in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy.
* SAR443122: Sanofi
SAR443122 is a peripherally-restricted small molecule inhibitor of RIPK1 being evaluated in patients with cutaneous lupus erythematosus (CLE). Denali and Sanofi entered into a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors. This includes peripherally restricted molecules such as SAR443122 (DNL758) and CNS-penetrant molecules such as DNL788 (SAR443820). A Phase II clinical study is assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus.
The Cutaneous Lupus Erythematosus Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous Lupus Erythematosus with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous Lupus Erythematosus Treatment.
* Cutaneous Lupus Erythematosus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Cutaneous Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous Lupus Erythematosus market
Stay informed about the Cutaneous Lupus Erythematosus pipeline trends @ Cutaneous Lupus Erythematosus Unmet Needs [https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cutaneous Lupus Erythematosus Companies
Hoth Therapeutics, Zylo Therapeutics, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, and Horizon Therapeutics and others.
Cutaneous Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical.
Cutaneous Lupus Erythematosus Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
Transform your understanding of the Cutaneous Lupus Erythematosus Pipeline @ Cutaneous Lupus Erythematosus Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Cutaneous Lupus Erythematosus Pipeline Report
* Coverage- Global
* Cutaneous Lupus Erythematosus Companies- Hoth Therapeutics, Zylo Therapeutics, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, and Horizon Therapeutics and others.
* Cutaneous Lupus Erythematosus Pipeline Therapies- Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran, and others.
* Cutaneous Lupus Erythematosus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cutaneous Lupus Erythematosus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Access the Full Cutaneous Lupus Erythematosus Pipeline Analysis Today! @ Cutaneous Lupus Erythematosus Drugs and Companies [https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Cutaneous Lupus Erythematosus: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cutaneous Lupus Erythematosus - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Cutaneous Lupus Erythematosus Collaboration Deals
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Mid Stage Products (Phase II)
* SAR443122: Sanofi
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* VIB7734: Horizon Therapeutics
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* HT-005 Z-Pods: Hoth Therapeutics/Zylo Therapeutics
* Inactive Products
* Cutaneous Lupus Erythematosus Key Companies
* Cutaneous Lupus Erythematosus Key Products
* Cutaneous Lupus Erythematosus- Unmet Needs
* Cutaneous Lupus Erythematosus- Market Drivers and Barriers
* Cutaneous Lupus Erythematosus- Future Perspectives and Conclusion
* Cutaneous Lupus Erythematosus Analyst Views
* Cutaneous Lupus Erythematosus Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cutaneous-lupus-erythematosus-clinical-trial-pipeline-accelerates-as-10-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cutaneous Lupus Erythematosus Clinical Trial Pipeline Accelerates as 10+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight here
News-ID: 4428669 • Views: …
More Releases from ABNewswire
Hodgkin's Lymphoma Pipeline Expands as 15+ Pharma Companies Advance 20+ Novel Th …
DelveInsight's "Hodgkin's Lymphoma - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies, including Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others, developing several pipeline drugs in the Hodgkin's Lymphoma pipeline landscape.
DelveInsight's "Hodgkin's Lymphoma - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies developing several pipeline drugs in the Hodgkin's Lymphoma pipeline landscape. It covers the…
Novartis's COSENTYX (Secukinumab) Approved by the FDA for Pediatric Hidradenitis …
DelveInsight Analysis: What Novartis's COSENTYX (Secukinumab) Approval by the FDA for Pediatric Hidradenitis Suppurativa Means for the Hidradenitis Suppurativa Treatment Market, Biologic Competition, and Commercial Strategy?
On March 13, 2026, Novartis announced that the FDA granted approval for COSENTYX (secukinumab) for the treatment of moderate to severe hidradenitis suppurativa (HS) in pediatric patients aged 12 years and older weighing at least 30 kg. The approval marks the fourth pediatric indication for…
Mammography Devices Market Poised for Robust Growth at 8.25% CAGR Through 2034: …
The global mammography devices market is set for strong, sustained expansion, driven by companies such as, SternMed GmbH, FUJIFILM Corporation, Hologic Inc., Planmed OY, General Electric Company (GE Healthcare), Siemens Healthcare GmbH, Koninklijke Philips NV, DMS Group, IMS Giotto S.P.A, General Medical Merate S.p.A, Konica Minolta Inc., Lanmage, Crestream Health, MEDI-FUTURE Inc. and others.
The global mammography devices market is set for strong, sustained expansion, driven by rising breast cancer incidence,…
Fetal Monitoring Devices Market Set for Steady Growth at 6.34% CAGR Through 2034 …
The global fetal monitoring devices market is set for strong, sustained expansion, driven by companies such as General Electric Company (GE Healthcare), Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Cardinal Health, Inc., Siemens Healthcare GmbH, Natus Medical Incorporated, Huntleigh Healthcare Limited, Clinical Computer Systems, Inc., Edan Instruments, Inc., Neoventa Medical AB, Arjo, Bionet, Contec Medical Systems Co., Ltd. and others.
The global fetal monitoring devices market is set for strong, sustained expansion,…
More Releases for Cutaneous
Cutaneous Lupus Erythematosus (CLE) Market
Introduction
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disorder, often associated with systemic lupus erythematosus (SLE), that presents as inflammation, rashes, and photosensitivity. While CLE is rarely fatal, it significantly affects patients' physical and emotional well-being, often leading to scarring, disfigurement, and social stigma.
Over the past decade, the market for CLE therapies has gained global importance as research into autoimmunity has accelerated and biologic therapies have transformed dermatology. Rising…
Cutaneous Angiosarcoma Market New Product Development & Latest Trends
Introduction
Cutaneous angiosarcoma is a rare and aggressive malignancy that originates from endothelial cells lining blood vessels and lymphatics in the skin. Though it represents a small fraction of soft-tissue sarcomas, its high recurrence rates, metastatic potential, and poor prognosis make it one of the most challenging cancers to manage. The condition most frequently affects elderly patients and is often associated with chronic lymphedema, prior radiation exposure, or immunosuppression.
Traditional management has…
Emerging Trends Influencing The Growth Of The Cutaneous T-Cell Lymphoma Market: …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Cutaneous T-Cell Lymphoma Market Size Expected to Be by 2034?
The market for cutaneous T-cell lymphoma has witnessed substantial growth in the past few years. It is projected to rise from a size of $2.54 billion in 2024 to $2.72 billion in 2025, equating to a compound annual…
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Key Trend Reshaping the Cutaneous Lupus Erythematosus Market in 2025: Advancemen …
What Are the Projections for the Size and Growth Rate of the Cutaneous Lupus Erythematosus Market?
The market size for cutaneous lupus erythematosus has seen quick expansion in the past few years. The growth is estimated to move from $2.24 billion in 2024 to $2.51 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.0%. This considerable increase in the historic period is a result of factors such as…
Cutaneous Lupus Erythematosus Market Trends & Analysis Report 2024
"The Business Research Company recently released a comprehensive report on the Global Cutaneous Lupus Erythematosus Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
